SecBot SecBot
SECBOTREPLAY Home › Report › INM

INM · InMed Pharmaceuticals filed a Rule 425 communication reporting FY2026…

InMed Pharmaceuticals Inc. · 425 filed Sep 9, 2026 at 16:54 ET

At the news

NEUTRALIMPACT 6/10

425 filed Sep 9, 2026 at 16:54 ET

InMed Pharmaceuticals filed a Rule 425 communication reporting FY2026 annual results and providing a corporate update on its proposed merger with Mentari Therapeutics. The net loss widened to $12.6M from $8.2M, cash burned to $2.2M, and the company is a pre-revenue shell whose value is entirely tied to the pending reverse-merger into Mentari, which has raised ~$490M in pre-closing financing. The merger remains on track for Q4 2026 close, but InMed's standalone financials show a deteriorating cash position and no operating revenue, making this a binary event on deal completion.

  • Net loss widened to $12.6M for FY2026 vs $8.2M in FY2025
  • Cash and short-term investments fell to $2.2M from $10.7M year-over-year
  • Merger with Mentari Therapeutics on track for Q4 2026 close; combined company to trade as MTRI
  • Mentari raised ~$490M total pre-closing financing ($290M May + $200M July 2026)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access